Found: 7
Select item for more details and to access through your institution.
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
- Published in:
- 2022
- By:
- Publication type:
- journal article
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Cabazitaxel Plus Lapatinib as Therapy for HER2<sup>+</sup> Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
- Published in:
- Clinical Breast Cancer, 2015, v. 15, n. 4, p. 251, doi. 10.1016/j.clbc.2014.09.007
- By:
- Publication type:
- Article
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 463, doi. 10.1007/s10637-015-0218-6
- By:
- Publication type:
- Article
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
- Published in:
- Cancer Medicine, 2015, v. 4, n. 5, p. 673, doi. 10.1002/cam4.376
- By:
- Publication type:
- Article
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
- Published in:
- 2018
- By:
- Publication type:
- journal article